Article
Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.
PloS one - 1 Jan 2014
Paíno Teresa, Sarasquete María E, Paiva Bruno, Krzeminski Patryk, San-Segundo Laura, Corchete Luis A, Redondo Alba, Garayoa Mercedes, García-Sanz Ramón, Gutiérrez Norma C, Ocio Enrique M, San-Miguel Jesús F
Abstract excerpt
Despite recent advances in the treatment of multiple myeloma (MM), it remains an incurable disease potentially due to the presence of resistant myeloma cancer stem cells (MM-CSC). Although the presence of clonogenic cells in MM was described three decades ago, the phenotype of MM-CSC is still controversial, especially with respect to the expression of syndecan-1 (CD138). Here, we demonstrate the presence of two...
Topics
- Animals
- Boronic Acids
- Bortezomib
- Cell Line, Tumor
- DNA Copy Number Variations
- Doxorubicin
- Heterografts
- Humans
- Immunophenotyping
- Melphalan
- Mice, SCID
- Multiple Myeloma
- Neoplastic Stem Cells